journal
MENU ▼
Read by QxMD icon Read
search

JAMA Oncology

journal
https://www.readbyqxmd.com/read/28910460/sudden-flank-pain-in-a-patient-receiving-ibrutinib-for-mantle-cell-lymphoma
#1
Yu Xi Terence Law, Lui Shiong Lee
No abstract text is available yet for this article.
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28910456/identification-of-alk-rearrangements-in-malignant-peritoneal-mesothelioma
#2
Yin P Hung, Fei Dong, Jaclyn C Watkins, Valentina Nardi, Raphael Bueno, Paola Dal Cin, John J Godleski, Christopher P Crum, Lucian R Chirieac
Importance: Malignant peritoneal mesothelioma is a rare, aggressive tumor arising from the peritoneal lining, induced by asbestos, therapeutic radiation, or germline mutations. Nevertheless, the molecular features remain largely unknown. Objective: To investigate anaplastic lymphoma kinase (ALK) rearrangements in a large series of peritoneal mesothelioma and characterize the mutational landscape of these tumors. Design, Setting, and Participants: We studied 88 consecutive patients (39 men, 49 women; median age 61, range 17-84 years) with peritoneal mesotheliomas diagnosed at a single institution between 2005 and 2015...
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28910441/faith-healer
#3
Roger Sippl
No abstract text is available yet for this article.
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28910437/the-difficult-transition
#4
Marni B Siegel
No abstract text is available yet for this article.
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28910433/error-in-figure-and-methods-section
#5
(no author information available yet)
No abstract text is available yet for this article.
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28910432/is-there-merit-for-met-targeted-therapies-in-gastroesophageal-cancer
#6
Massimiliano Mazzone, Veronica Finisguerra, Hans Prenen
No abstract text is available yet for this article.
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28910431/hla-mismatched-microtransplant-in-older-patients-newly-diagnosed-with-acute-myeloid-leukemia-results-from-the-microtransplantation-interest-group
#7
Mei Guo, Nelson J Chao, Jian-Yong Li, David A Rizzieri, Qi-Yun Sun, Ann Mohrbacher, Elizabeth F Krakow, Wan-Jun Sun, Xu-Liang Shen, Xin-Rong Zhan, De-Pei Wu, Li Liu, Juan Wang, Min Zhou, Lin-Hua Yang, Yang-Yi Bao, Zheng Dong, Bo Cai, Kai-Xun Hu, Chang-Lin Yu, Jian-Hui Qiao, Hong-Li Zuo, Ya-Jing Huang, Anthony D Sung, Jun-Xiao Qiao, Zhi-Qing Liu, Tie-Qiang Liu, Bo Yao, Hong-Xia Zhao, Si-Xuan Qian, Wei-Wei Liu, Rafael Forés, Rafael F Duarte, Hui-Sheng Ai
Importance: The outcome of older patients with acute myeloid leukemia (AML) remains unsatisfactory. Recent studies have shown that HLA-mismatched microtransplant could improve outcomes in such patients. Objective: To evaluate outcomes in different age groups among older patients with newly diagnosed AML who receive HLA-mismatched microtransplant. Design, Setting, and Participants: This multicenter clinical study included 185 patients with de novo AML at 12 centers in China, the United States, and Spain in the Microtransplantation Interest Group...
September 14, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28880983/chimeric-antigen-receptor-car-t-cell-therapy
#8
John M Pagel, Howard Jack West
No abstract text is available yet for this article.
September 7, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28880981/timing-of-pregnancy-and-survival-in-women-with-breast-cancer
#9
Samer Al Hadidi
No abstract text is available yet for this article.
September 7, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28880976/the-waiting-room
#10
Roger Sippl
No abstract text is available yet for this article.
September 7, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28880973/a-new-monoclonal-protein-detected-in-a-patient-with-myeloma-undergoing-elotuzumab-therapy
#11
Felicia Tang, Christine Schmotzer, Rose C Beck
No abstract text is available yet for this article.
September 7, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28880972/effect-of-modified-vaccinia-ankara-5t4-and-low-dose-cyclophosphamide-on-antitumor-immunity-in-metastatic-colorectal-cancer-a-randomized-clinical-trial
#12
Martin Scurr, Tom Pembroke, Anja Bloom, David Roberts, Amanda Thomson, Kathryn Smart, Hayley Bridgeman, Richard Adams, Alison Brewster, Robert Jones, Sarah Gwynne, Daniel Blount, Richard Harrop, Melissa Wright, Robert Hills, Awen Gallimore, Andrew Godkin
Importance: The success of immunotherapy with checkpoint inhibitors is not replicated in most cases of colorectal cancer; therefore, different strategies are urgently required. The oncofetal antigen 5T4 is expressed in more than 90% of cases of metastatic colorectal cancer (mCRC). Preliminary data using modified vaccinia Ankara-5T4 (MVA-5T4) in mCRC demonstrated that it safely induced serologic and T-cell responses. Objective: To determine whether antitumor immunity in mCRC could be increased using MVA-5T4, metronomic low-dose cyclophosphamide, or a combination of both treatments...
September 7, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28880971/development-and-validation-of-a-novel-acute-myeloid-leukemia-composite-model-to-estimate-risks-of-mortality
#13
Mohamed L Sorror, Barry E Storer, Amir T Fathi, Aaron T Gerds, Bruno C Medeiros, Paul Shami, Andrew M Brunner, Mikkael A Sekeres, Sudipto Mukherjee, Esteban Peña, Mahmoud Elsawy, Shylo Wardyn, Jennifer Whitten, Rachelle Moore, Pamela S Becker, Jeannine S McCune, Frederick R Appelbaum, Elihu H Estey
Importance: To our knowledge, this multicenter analysis is the first to test and validate (1) the prognostic impact of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia (AML) and (2) a novel, risk-stratifying composite model incorporating comorbidities, age, and cytogenetic and molecular risks. Objective: To accurately estimate risks of mortality by developing and validating a composite model that combines the most significant patient-specific and AML-specific features...
September 7, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28859199/mise-en-place
#14
Carlos A Rodriguez-Russo
No abstract text is available yet for this article.
August 31, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28859194/validity-of-surrogate-end-points-for-prostate-cancer-reply
#15
Trevor J Royce, Ming-Hui Chen, Anthony V D'Amico
No abstract text is available yet for this article.
August 31, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28859193/validity-of-surrogate-end-points-for-prostate-cancer
#16
Stuart G Baker
No abstract text is available yet for this article.
August 31, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28859189/trends-in-adult-cancer-related-emergency-department-utilization-an-analysis-of-data-from-the-nationwide-emergency-department-sample
#17
Donna R Rivera, Lisa Gallicchio, Jeremy Brown, Benmei Liu, Demetrios N Kyriacou, Nonniekaye Shelburne
Importance: The emergency department (ED) is used to manage cancer-related complications among the 15.5 million people living with cancer in the United States. However, ED utilization patterns by the population of US adults with cancer have not been previously evaluated or described in published literature. Objective: To estimate the proportion of US ED visits made by adults with a cancer diagnosis, understand the clinical presentation of adult patients with cancer in the ED, and examine factors related to inpatient admission within this population...
August 31, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28859185/salvage-chemoimmunotherapy-with-inotuzumab-ozogamicin-combined-with-mini-hyper-cvd-for-patients-with-relapsed-or-refractory-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia-a-phase-2-clinical-trial
#18
Elias Jabbour, Farhad Ravandi, Partow Kebriaei, Xuelin Huang, Nicholas J Short, Deborah Thomas, Koji Sasaki, Michael Rytting, Nitin Jain, Marina Konopleva, Guillermo Garcia-Manero, Richard Champlin, David Marin, Tapan Kadia, Jorge Cortes, Zeev Estrov, Koichi Takahashi, Yogin Patel, Maria R Khouri, Jovitta Jacob, Rebecca Garris, Susan O'Brien, Hagop Kantarjian
Importance: The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. Objective: To evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy in patients with R/R ALL. Design, Setting, and Participants: A single-arm, phase 2 study of adults with R/R B-cell ALL conducted at The University of Texas MD Anderson Cancer Center, Houston...
August 31, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28837720/errors-in-tables
#19
(no author information available yet)
No abstract text is available yet for this article.
August 24, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28837718/adjuvant-chemotherapy-vs-observation-for-patients-with-adverse-pathologic-features-at-radical-cystectomy-previously-treated-with-neoadjuvant-chemotherapy
#20
Thomas Seisen, Asha Jamzadeh, Jeffrey J Leow, Morgan Rouprêt, Alexander P Cole, Stuart R Lipsitz, Adam S Kibel, Paul L Nguyen, Maxine Sun, Mani Menon, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
Importance: Despite existing evidence of a benefit associated with cisplatin-based adjuvant chemotherapy (AC) after radical cystectomy (RC) for chemotherapy-naive patients with pT3/T4 and/or pN+ urothelial carcinoma of the bladder (UCB), to our knowledge, no studies have addressed the effectiveness of AC in those who received neoadjuvant chemotherapy (NAC) before surgery. Objective: To assess the comparative effectiveness of AC vs observation for patients with pT3/T4 and/or pN+ UCB previously treated with NAC and RC...
August 24, 2017: JAMA Oncology
journal
journal
50067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"